PTC Therapeutics' gene therapy is already approved in the European ... alongside the dollar on Thursday as investors bet that ...
Improvements to premium tax credits, enacted in the American Rescue Plan and extended by the Inflation Reduction Act, have ...
Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
In a report released today, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $45.00. The company’s shares closed yesterday at ...
PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...
Antitrust enforcement is likely to return to its established norms, Jay Ezrielev writes in a guest commentary.
Researchers say RTO mandates could hurt women and underrepresented workers, who are more likely to avoid companies that don’t ...
The containment policy set in the first Trump administration and continued under President Biden will get a harder edge, ...
You are responsible for reading, understanding, and agreeing to the National Law Review's (NLR’s) and the National Law Forum ...
State police are providing new details on the allegations against the executive director of the Greater Altoona Career and ...
A recent rulemaking regarding patient care decision support tools is an important step forward in ensuring safety and equity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback